目的 探讨曲美他嗪对糖尿病心肌病(DCM)患者血清超敏C反应蛋白(hs-CRP)、氨基末端脑钠肽前体(NT-proBNP)及Tei指数的影响.方法 选取2015年1月至2017年1月收住重庆市巴南区人民医院血管内科和内分泌科的90例DCM患者为研究对象,按随机数表法分为对照组和观察组各45例,对照组予常规综合治疗,观察组在常规综合治疗基础上加用曲美他嗪片口服治疗,疗程均为10周.比较两组患者入院时及治疗10周后hs-CRP、NT-proBNP水平及Tei指数的差异.结果 两组患者入院后的hs-CRP、NT-proBNP水平及Tei指数比较差异均无统计学意义(P>0.05);治疗10周后,观察组和对照组患者的hs-CRP[(5.2±1.2)mg/L vs(6.5±1.7)mg/L]、NT-proBNP[(231.65±71.39)pg/L vs(314.31±85.21)pg/L]和Tei指数[(0.502±0.021)vs(0.541±0.016)]比较,观察组均较对照组明显下降,差异均有统计学意义(P<0.05);两组患者治疗期间均未发现严重的药物相关不良事件.结论 曲美他嗪能够显著降低DCM患者血清hs-CRP、NT-proBNP水平,改善患者Tei指数,提高临床疗效.%Objective To investigate the effects of trimetazidine on diabetic cardiomyopathy (DCM) pa-tients' hypersensitive C-reactive protein (hs-CRP), N-terminal pro-natriuretic peptide (NT-proBNP) and Tei index. Methods A total of 90 DCM patients, who admitted to Department of Cardiology and Endocrinology in Chongqing Banan District People's Hospital from Jan.2015 to Jan.2017,were selected and randomly divided into the observation group and control group according to the random number table method,with 45 cases in each group.The control group was given conventional treatment, and the observation group was treated with trimetazidine additionally. Both groups were treated continuously for 10 weeks.The serum hs-CRP,NT-proBNP concentration and Tei index of the two groups before treatment and ten weeks after treatment were compared.Results At admission,there were no significant differ-ences between the two groups in patients'plasma values of hs-CRP,NT-proBNP and Tei index(P>0.05).After ten weeks of treatment,the serum hs-CRP,NT-proBNP concentration and Tei index in the observation group were(5.2±1.2)mg/L, (231.65±71.39)pg/L,(0.502±0.021),respectively,which were significantly lower than corresponding(6.5±1.7)mg/L, (314.31±85.21)pg/L,(0.541±0.016)in the control group(P<0.05).No severe side effect was found in both groups dur-ing therapy.Conclusion Trimetazidine can significantly decrease the levels of serum hs-CRP and NT-proBNP,improve Tei index,and increase the clinical efficacy.
展开▼
